Alkermes' (ALKS) Nemvaleukin Alfa Granted FDA Fast Track Designation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Pre-Open Stock Movers 08/02: (XCUR) (DLPN) (AUTL) Higher; (PH) (SQ) Lower (more...)
August 2, 2021 9:31 AM EDTPre-Open Stock Movers:
Exicure Inc. (NASDAQ: XCUR) 35.5% HIGHER; Ipsen (Euronext: IPN; ADR: IPSEY) and Exicure Inc. (NASDAQ: XCUR) have signed an exclusive collaboration agreement to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational treatments for Huntingtons disease and Angelman syndrome.
Dolphin Entertainment (NASDAQ: DLPN) 27% HIGHER; Hall of Fame Resort and Entertainment Company (NASDAQ: HOFV, HOFVW) and Dolphin Entertainment (NASDAQ: DLPN) announce the creation of a new NFT... More
Alkermes (ALKS) Granted FDA Fast Track Designation for Nemvaleukin Alfa
August 2, 2021 7:02 AM EDTAlkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nemvaleukin alfa (nemvaleukin), the company's novel, investigational engineered interleukin-2 (IL-2) variant immunotherapy, for the treatment of mucosal melanoma. Earlier this year, the FDA also granted... More
Alkermes (ALKS) PT Raised to $33 at Mizuho Securities
July 29, 2021 6:33 AM EDTMizuho Securities analyst Vamil Divan raised the price target on Alkermes (NASDAQ: ALKS) to $33.00 (from $29.00) while maintaining a Buy rating.... More
